187393-68-6

Basic information

• Product Name: (E)-N-(6-aMino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyriMidin-5-yl)-3-(3,4-diMethoxyphenyl)acrylaMide
• Synonyms: (E)-N-(6-aMino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyriMidin-5-yl)-3-(3,4-diMethoxyphenyl)acrylaMide;(2E)-N-(6-amino-1,3-diethyl-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)acrylamide
• CAS NO: 187393-68-6
• Molecular Formula: C₁₉H₂₄N₄O₅
• Molecular Weight: 388.41766
• Mol File: 187393-68-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-N-(6-aMino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyriMidin-5-yl)-3-(3,4-diMethoxyphenyl)acrylaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-(6-aMino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyriMidin-5-yl)-3-(3,4-diMethoxyphenyl)acrylaMide(187393-68-6)
• EPA Substance Registry System: (E)-N-(6-aMino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyriMidin-5-yl)-3-(3,4-diMethoxyphenyl)acrylaMide(187393-68-6)

Safety Data

• Hazardous Substances Data: 187393-68-6(Hazardous Substances Data)

Usage

General Description

(E)-N-(6-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(3,4-dimethoxyphenyl)acrylamide is a complex synthetic compound featuring pyrimidine, phenyl, and acrylamide functional groups. The structure suggests that it may have a number of interesting chemical properties and potential biological activities. Its pyrimidine segment, which contains a six-membered ring with two nitrogen atoms and a keto group, is a common structural motif in biological molecules, including nucleotides, the building blocks of DNA and RNA. The phenyl segment with methoxy substituents could potentially result in antioxidative or antiviral properties. Lastly, the acrylamide group, a common reactive unit in polymers, suggests that this compound could potentially be used in the creation of novel materials or chemical reactions. However, without specific literature or studies, the exact properties and applications of this molecule remain speculative.

Upstream product

• 52998-22-8 5,6-diamino-1,3-diethyluracil 
• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 634-95-7 N,N-diethylurea 
• 41740-15-2 6-amino-1,3-diethyluracil 
• 89073-60-9 6-amino-1,3-diethyl-5-nitroso-1H,3H-pyrimidine-2,4-dione 
• 39856-08-1 (E)-3,4-dimethoxycinnamic chloride 

Downstream Products

• 155270-99-8 istradefylline 
• 155270-98-7 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione 

Relevant articles and documents

A Iraq curved theophylline preparation of intermediate

The present invention provides a kind of Iraq curved theophylline intermediate (E)- 1, 3 - diethyl - 6 - amino - 5 - (3, 4 - dimethoxy acryloyl) amino uracil preparation method, comprising the following steps: 1, 3 - diethyl - 5, 6 - diamino uracil as raw materials, methylene chloride as the solvent, triethylamine as acid-binding agent, slowly add (E) 3, 4 - dimethoxy acryloyl chloride, reaction, washes the acid, water crystallization, shall (E)- 1, 3 - diethyl - 6 - amino - 5 - (3, 4 - dimethoxy acryloyl) amino uracil; the invention provides a preparation method, to separate out the product from the organic layer, can make the reactant and by-product effective separation, get of the Iraqi curved theophylline intermediate high purity, the operation is simple.

Improved synthesis technology of istradefylline

The invention provides an improved synthesis technology of istradefylline. According to the technology, istradefylline is prepared from 1,3-diethyl-6-amino-5-nitrosouracil (SM-III) as a starting material through four steps.

Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's Disease

The improved multigram-scale syntheses of the important 8-styrylxanthine A2A adenosine receptor antagonist MSX-2 (8), its water-soluble prodrug MXS-3 (9), and KW-6002 (16) are described. N-Alkylation reactions at different positions of uracil derivatives were optimized. Two different methods for xanthine formation from 6-amino-5-cinnainoylaminouracil precursors were investigated, (a) the elimination of water by alkaline catalysis and (b) hexamethyldisilazane as a condensing agent; the latter was found to be superior. The photosensitivity of 8-styrylxanthines was studied. The (E)-configurated stryrylxanthine MSX-2 (8) isomerized in diluted solution, and the resulting (Z)-isomer (10a) was isolated and characterized. Furthermore, we describe for the first time that solid 8-styrylxanthines can dimerize upon exposition to daylight or irradiation with UV light. The resulting cyclobutane derivatives with head-to-tail (syn) configuration exhibited a considerably lower A 2A adenosine receptor affinity than their parent compounds. The dimerization product of MSX-2 was a moderately potent nonselective A 1 and A2A antagonist (Ki(Ai) = 273 nM, Ki(A2A) = 175 nM) while the dimer of the related compound KW-6002 was inactive at A1 and only weakly active at A 2A adenosine receptors (Ki = 1.57 μM). The light sensitivity of 8-styrylxanthine derivatives, not only in solution, but also in the solid state, has to be considered when using those compounds as pharmacological tools or drugs.